Get the Stockscreener App
1.8901
0.78%
-0.0149
After Hours:
1.89
-0.000100
-0.01%
Immuron Limited Adr stock is traded at $1.8901, with a volume of 7,291.
It is down -0.78% in the last 24 hours and down -2.67% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$1.905
Open:
$1.87
24h Volume:
7,291
Relative Volume:
1.01
Market Cap:
$11.17M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.2996
EPS:
-0.4396
Net Cash Flow:
-
1W Performance:
+0.08%
1M Performance:
-2.67%
6M Performance:
-16.00%
1Y Performance:
-2.07%
1-Day Range:
$1.87
$1.9899
1-Week Range:
$1.8001
$1.9899
52-Week Range:
$1.59
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.8901 | 11.17M | 2.35M | -2.56M | 0 | -0.4396 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron requests pre-IND meeting for IMM-529 with FDA filing | Daily Guardian - Daily Guardian Canada
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Immuron Surges On U.S. DoD Funding For Travelan Research - Yahoo Movies UK
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug - Stockhead
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed - Stockhead
45 Stocks Moving in Tuesday's Pre-Market SessionArbutus Biopharma (NASDAQ:ABUS), ACADIA Pharmaceutical - Benzinga
36 Stocks Moving in Monday's Pre-Market Session - Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortf - Benzinga
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
29 Stocks Moving In Wednesday's Mid-Day SessionBabcock & Wilcox (NYSE:BW), AstroNova (NASDAQ:ALOT) - Benzinga
35 Stocks Moving In Tuesday's Mid-Day SessionAyala Pharmaceuticals (OTC:ADXS) - Benzinga
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):